NEW YORK (GenomeWeb News) – The Serious Adverse Events Consortium has selected Expression Analysis as the exclusive provider of genotyping services for its first research project, the genomic services firm said yesterday.
The first project will focus on liver toxicity using samples provided by DILIGEN and EUDRAGENE, two European clinical research networks. Expression Analysis said that it will use Illumina's Human 1M DNA Analysis BeadChip to perform the genotyping on these samples.
The SAEC, launched last month, is a collaboration between the US Food and Drug Administration, several pharmaceutical companies, and academic research groups to identify genetic biomarkers that may predict which individuals are at risk for drug-related adverse events.
Arthur Holden, chairman of the SAEC, said in a statement that the consortium’s scientific management committee “independently evaluated many competing proposals and selected Expression Analysis based on its extensive ‘quality system’ and service track record.”